Lisata Therapeutics Inc (LSTA)

[Viperciara]

Caladrius Biosciences (NASDAQ:CLBS) Receives $10.80 Consensus PT from Analysts

Posted on December 17, 2015 by Micah Smith in Investing, Consensus Rating Articles

Caladrius Biosciences logoCaladrius Biosciences (NASDAQ:CLBS) has received an average rating of “Buy” from the seven analysts that are currently covering the stock, AnalystRatingsNetwork.com reports. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $10.80.

Caladrius Biosciences (NASDAQ:CLBS) opened at 1.06 on Monday. Caladrius Biosciences has a one year low of $1.02 and a one year high of $4.26. The stock’s market capitalization is $58.70 million. The firm has a 50-day moving average of $1.19 and a 200 day moving average of $1.57.

Several analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Caladrius Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, November 26th. Maxim Group restated a “buy” rating on shares of Caladrius Biosciences in a report on Thursday, September 24th. Finally, WBB Securities restated a “buy” rating and issued a $7.00 price objective on shares of Caladrius Biosciences in a report on Thursday, September 24th.

Caladrius Biosciences, Inc., formerly NeoStem, Inc., is a clinical-stage biopharmaceutical company. The Company’s clinical program is based on its dendritic cell and cancer cell technology. It is focused on the development of a cancer treatment designed to focus the cells responsible for tumor growth and metastasis, known as cancer or tumor initiating cells (NASDAQ:CLBS). Its lead product candidate based on this platform technology is NBS20 (targeted cancer immunotherapy), which is in Phase II trials focuses on malignant melanoma as an initial indication. Its therapeutic platforms also include ischemic repair (CD34 Cell Program) and immune modulation (T Regulatory Cell Program). Its CD34 Cell Program develops therapies designed to address diseases and conditions caused by ischemia. Its product candidate in CD34 Cell Program is NBS10, which has completed Phase I clinical trials. Under T Regulatory Cell Program, the Company is developing NBS03D, which is in the Phase I clinical trial stage.document.write(‘‘);
http://www.storminvestor.com/caladrius-biosciences-nasdaqclbs-receives-10-80-consensus-pt-from-analysts/186461/